Fundraising Fox

KALA BIO

NASDAQ: KALA

Arlington, US · Founded 2009 · Delaware corporation · 6 known investors

Biotech

Founders & leadership

DK
Darius KharabiExecutive
TB
Todd BazemoreExecutive
MI
Mark IwickiExecutive
MR
Mary ReumuthExecutive
KB
Kim BrazzellExecutive
CM
Charles McDermottExecutive
HC
Hongming ChenExecutive
RL
Robert LangerNamed on SEC filing
JH
Justin HanesNamed on SEC filing
KP
Kevin PojasekNamed on SEC filing
PC
Peter CourossiNamed on SEC filing

Board

KBKevin Bitterman
Kevin Bittermanin𝕏Board directorPartner at Atlas Venture

Investors · 6

Longitude CapitalMenlo Park · $10M – $30M
SR One Capital ManagementRedwood City
Ysios CapitalBarcelona · $5.4M – $21.6M
Atlas VenturereportedCambridge · $500K – $1Mvia Kevin Bitterman · board
Lux CapitalreportedNew York · $100K – $100Mvia Robert Paull · board
Third Rock VenturesreportedBoston · $100K – $5Mvia Robert Tepper · board

Reported raises · per SEC filings

Form D private placements

$148M disclosed across 9 rounds · 2012–2026

▶$1.8MraisedMar 2026 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Yonatan ColmanDirector
  • Brendan PurdyDirector
  • Chaim BergerDirector
  • Avi MinkowitzExecutive Officer, Director
  • Hillel PosenDirector
Offering amount
$1.8M
Amount sold
$1.8M
Minimum investment
$1.8M
First sale
Mar 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.3MraisedFeb 2026 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • CHAIM BERGERDirector
  • HILLEL POSENDirector
  • AVI MINKOWITZExecutive Officer, Director
  • DAVID LAZARDirector
  • BRENDAN PURDYDirector
  • YONATAN COLMANDirector
Offering amount
$4.2M
Amount sold
$2.3M
Minimum investment
$44.9K
Sales commissions
$39K
Placement agents
FM Global Markets Inc.
First sale
Jan 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.7MraisedDec 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Darius KharabiExecutive Officer
  • Todd BazemoreExecutive Officer
  • Gregory D. PerryDirector
  • Marjan FaridDirector
  • Andrew I. KovenDirector
  • Howard B. RosenDirector
  • Mark IwickiExecutive Officer, Director
  • Mary ReumuthExecutive Officer
  • C. Daniel MyersDirector
  • Kim BrazzellExecutive Officer
Offering amount
$10.7M
Amount sold
$10.7M
First sale
Dec 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$12.5MraisedJun 2024 · 5 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark IwickiExecutive Officer, Director
  • Kim BrazzellExecutive Officer
  • Marjan FaridDirector
  • Todd BazemoreExecutive Officer
  • Mark S. BlumenkranzDirector
  • Mary ReumuthExecutive Officer
  • C. Daniel MyersDirector
  • Darius KharabiExecutive Officer
  • Gregory D. PerryDirector
  • Andrew I. KovenDirector
  • Howard B. RosenDirector
Offering amount
$12.5M
Amount sold
$12.5M
First sale
Jun 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.1MraisedNov 2021 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kim BrazzellExecutive Officer
  • Gregory D. PerryDirector
  • Mary ReumuthExecutive Officer
  • Mark S. BlumenkranzDirector
  • Andrew KovenDirector
  • Darius KharabiExecutive Officer
  • Howard B. RosenDirector
  • Gregory GrunbergDirector
  • Mark IwickiExecutive Officer, Director
  • Hongming ChenExecutive Officer
  • Robert PaullDirector
  • Eric L. TrachtenbergExecutive Officer
  • C. Daniel MyersDirector
  • Todd BazemoreExecutive Officer
Offering amount
$36.5M
Amount sold
$16.1M
First sale
Nov 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$67.9MraisedApr 2016 · 25 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kevin BittermanDirector
  • Chen YuDirector
  • Kim BrazzellExecutive Officer
  • Charles McDermottExecutive Officer
  • Robert TepperDirector
  • Robert LangerDirector
  • Robert PaullDirector
  • Mark IwickiExecutive Officer, Director
  • Greg GrunbergDirector
  • Rajeev ShahDirector
  • Howard B. RosenDirector
  • Hongming ChenExecutive Officer
Offering amount
$67.9M
Amount sold
$67.9M
First sale
Apr 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedAug 2015 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Charles McDermottExecutive Officer
  • Kevin BittermanDirector
  • Robert TepperDirector
  • Robert PaullDirector
  • Kim BrazzellExecutive Officer
  • Howard B. RosenDirector
  • Karen WagnerDirector
  • Mark IwickiExecutive Officer, Director
  • Rajeev ShahDirector
  • Robert LangerDirector
  • Hongming ChenExecutive Officer
Offering amount
$7M
Amount sold
$7M
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$22.5MraisedApr 2014 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert TepperDirector
  • Kevin BittermanDirector
  • Robert PaullDirector
  • Kim BrazzellExecutive Officer
  • Howard B. RosenDirector
  • Guillaume PfeferExecutive Officer, Director
  • Bernard GillyDirector
  • Robert LangerDirector
Offering amount
$22.5M
Amount sold
$22.5M
First sale
Apr 2014
Incorporated
Corporation, Delaware, 2009
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through KALA BIO went on to found or lead other companies.

Robert PaullDirectorFounded Genocea BiosciencesKevin BittermanDirectorFounded Editas Medicine

Competitors · 2

by search overlap
Robinhood42 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
StockTwits33 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.

Companies competing with KALA BIO for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$255.6K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$180.4K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

KALA BIO Announces Brief Delay in Quarterly Filing - TipRanks.comtipranks.com · Aug 2026KALA BIO Announces New CEO and Funding Deal - TipRanks.comtipranks.com · Dec 2025KALA BIO Raises $10M in Direct Offering - TipRanks.comtipranks.com · Dec 2025KALA BIO Secures $10.75M Investment from Major Funds, Extends Cash Runway for Key Eye Treatment Trial | KALA Stock Newsstocktitan.net · Dec 2024

Frequently asked questions

Who are KALA BIO's investors?
KALA BIO's investors include Longitude Capital, SR One Capital Management, Ysios Capital, Atlas Venture, Lux Capital, Third Rock Ventures.
How much funding has KALA BIO raised?
KALA BIO has disclosed $148M raised across 9 rounds.
Where is KALA BIO headquartered?
KALA BIO is headquartered in Arlington, US.